NasdaqGS:ZBIOBiotechs
Zenas BioPharma (ZBIO) Is Up 9.4% After Wider Losses And Board Addition - Has The Bull Case Changed?
In August 2026, Zenas BioPharma, Inc. reported second-quarter and first-half 2026 results showing US$1,000,000 in quarterly revenue and a sharply higher net loss of US$111,460,000, while also announcing the upcoming transition of Chief Financial Officer Jennifer Fox to a Strategic Advisor role and interim financial leadership by President and COO Joe Farmer.
At the same time, Zenas added industry veteran Christy Oliger to its board, bringing extensive commercial experience from leading large...